Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
Sponsored Content On December 2, 2025, Imvax, Inc. announced top-line results from a Phase 2b clinical trial of IGV-001, an investigational autologous biologic-device combination product, in 99 adults with newly
When facing a diagnosis of glioma or glioblastoma (GBM), every scan, symptom and decision can feel deeply personal. Patients and families quickly learn how much depends on imaging — it
NX Development Corp (“NXDC”) is pleased to announce that it is once again distributing Gleolan® (aminolevulinic acid HCl) in the United States, supporting neurosurgeons in fluorescence-guided surgery for patients with
Glioblastoma is one of the most aggressive and deadly forms of brain cancer, notorious for its resistance to treatment and devastating prognosis. But a breakthrough approach from the company Carthera is
This article is sponsored by Virginia Commonwealth University. Fear of cancer recurrence (FCR) is a commonly-reported phenomenon across cancer populations, but has largely been overlooked among those diagnosed with brain
TakeAim Lymphoma – Now Enrolling ** Sponsored by Curis. This content is not an endorsement from the ABTA.** Primary CNS Lymphoma (PCNSL) Curis is a biopharmaceutical company dedicated to developing
** Sponsored by Pacific Neuroscience Institute (PNI). This content is not an endorsement from the ABTA.** By Emmaline Mauitson, MPAP, PA-C James, 75, was vacationing in Hawaii with his wife
** Sponsored by Ono Pharmaceuticals. This content is not an endorsement from the ABTA.** In her job at a healthcare insurer, Barb Brady leads a team that collaborates with primary
Always free for patients & caregivers
